Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Lung cancer pill 'a leap forward'

  • Comment

A personalised lung cancer pill launched on Monday offers new hope to sufferers of a rare form of the disease.

The drug, crizotinib, targets a protein found in around five in 100 patients with the most common type of lung cancer.

Typically, these patients are much younger than average and do not appear to have a disease closely linked to smoking.

Marketed as Xalkori, the treatment was given an early licence by regulators after promising trial findings.

A Phase III study of 347 patients found that the drug more than doubled the time taken for treated tumours to start growing again or stop shrinking.

So-called “progression free survival” was increased from a mid-point of three months for patients on chemotherapy to 7.7 months.

Although survival time was not studied, researchers believe the drug has the potential to extend lives.

Crizotinib is the latest in a new generation of cancer drugs tailored to individuals with specific genetic make-ups.

It acts on a protein called ALK which blocks anti-cancer signalling pathways.

Patients who can benefit from crizotinib are identified by analysing biopsy tissue samples. They form a distinct subgroup among patients with non-small cell lung cancer, which accounts for 80-85% of lung cancer cases.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.